Pegbio-B (02565.HK) Core Product Peidakang (Vipenatide Injection) Successfully Included in the 2026 National Reimbursement Drug List

Zhitong Finance APP news, Pegbio-B (02565.HK) announced that the Group's core innovative drug product independently developed by the Group, beinaglutide injection (trade name: Paidakang, hereinafter referred to as "Paidakang"), has been successfully included in the latest "2026 National Drug Catalogue for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance" published by the National Healthcare Security Administration.